Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2014 Sep 6;20(12):1996–2003. doi: 10.1016/j.bbmt.2014.08.020

Figure 2. Acute and chronic graft-vs.-host disease (GVHD).

Figure 2

Shown is the cumulative incidence of acute GVHD grades II-IV (panel A) and acute GVHD grades III-IV (panel B) according to whether patients were given thymoglobulin (dashed line, n = 22) or not given thymoglobulin (solid line, n = 9) in the regimen. Panel C shows the cumulative incidence of chronic GVHD. Panel D shows the cumulative incidence of discontinuation of systemic immune suppression following HCT.